BAC signs license agreement with Hematech

26-Mar-2008

BAC BV announced that it has entered into a license and supply agreement with Hematech, Inc., a subsidiary of Kirin Pharma that specialises in the production of human antibodies in transgenic cows. The license covers the use of a custom designed bovine IgG scavenging ligand which BAC had previously developed for Hematech. GE Healthcare will immobilize the BAC ligand on chromatographic media, which Hematech will use in the production of polyclonal human IgG from its transgenic cow platform.

"We have previously worked with Hematech to discover and develop the bovine IgG scavenging ligand and we are very pleased to continue this collaboration into a supply phase," said Laurens Sierkstra, CEO of BAC. "The success of this project further demonstrates the suitability of our ligands for a wide variety of applications and our ability to work in close partnership with collaborators to deliver ligands that exactly meet requirements."

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous